Abstract
This study was designed to investigate the pharmacodynamic interaction of co-administration of ezetimibe and omega-3-fatty acids on lipoproteins of mixed dyslipidemia in human subjects. Human male subjects were induced hyperlipidemia and they were divided into 4groups of 24 subjects in each group. The inclusion criteria were mixed dyslipidemia with a high triglyceride level (200-499mgper100ml) and a total cholesterol level more than 200mg per 100ml. Present study was conducted on dyslipidemic subjects receiving ezetimibe (10mg) alone, omega-3-fatty acids(4g) alone and combination of ezetimibe (10mg) and omega-3-fattyacids (4g) daily for 90days. After 90days treatment, (Tc, LDL ) was found decreased, Tg level reduced significantly and HDL level increased in the combination therapy ( ezetimibe and omega-3-fattyacids) than their mono therapies. From the result it was concluded that combination therapy of these two may be considered as an optimal treatment option for mixed dyslipidemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
